Real-world effectiveness of cariprazine in major depressive disorder and bipolar I disorder in the United States.

Journal: Journal of medical economics
Published Date: Jun 10, 2025

Abstract

AIMS: The efficacy of cariprazine for major depressive disorder (MDD) (adjunctive therapy) and bipolar I (BP-I) depression has been demonstrated in clinical trials. This study evaluated the real-world effectiveness of cariprazine in reducing depression severity among patients with moderate-to-severe MDD or BP-I depression.

Authors

  • Roger S McIntyre
    Institute of Medical Science, University of Toronto, Toronto, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada; Department of Pharmacology, University of Toronto, Toronto, Canada. Electronic address: Roger.McIntyre@uhn.ca.
  • Mousam Parikh
    AbbVie, North Chicago, IL, USA.
  • Jamie Ta
    AbbVie, North Chicago, IL, USA.
  • Simranpreet Waraich
    AbbVie, North Chicago, IL, USA.
  • Chandra Cohen-Stavi
    OM1, Inc., Boston, MA, USA.
  • Carl Marci
    OM1, Inc., Boston, MA, USA.
  • Nadia Nabulsi
    AbbVie, North Chicago, IL, USA.

Keywords

External Resources

Popular Topics
Recent Journals